Loading…
Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors
We investigated whether increasing levels of tissue hypoxia, measured by the binding of EF5 [2-(2-nitro-1- H -imidazol-1-yl)- N -(2,2,3,3,3-pentafluoropropyl) acetamide] or by Eppendorf needle electrodes, were associated with tumor aggressiveness in patients with previously untreated glial brain tum...
Saved in:
Published in: | Clinical cancer research 2004-12, Vol.10 (24), p.8177-8184 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | We investigated whether increasing levels of tissue hypoxia, measured by the binding of EF5 [2-(2-nitro-1- H -imidazol-1-yl)- N -(2,2,3,3,3-pentafluoropropyl) acetamide] or by Eppendorf needle electrodes, were associated with tumor aggressiveness in
patients with previously untreated glial brain tumors. We hypothesized that more extensive and severe hypoxia would be present
in tumor cells from patients bearing more clinically aggressive tumors. Hypoxia was measured with the 2-nitroimidazole imaging
agent EF5 in 18 patients with supratentorial glial neoplasms. In 12 patients, needle electrode measurements were made intraoperatively.
Time to recurrence was used as an indicator of tumor aggression and was analyzed as a function of EF5 binding, electrode values
and recursive partitioning analysis (RPA) classification. On the basis of EF5 binding, WHO grade 2 tumors were characterized
by modest cellular hypoxia (pO 2 s ≈ 10%) and grade 3 tumors by modest-to-moderate hypoxia (pO 2 s ≈ 10%- 2.5%). Severe hypoxia (≈0.1% oxygen) was present in 5 of 12 grade 4 tumors. A correlation between more rapid tumor
recurrence and hypoxia was demonstrated with EF5 binding, but this relationship was not predicted by Eppendorf measurements. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-04-1081 |